TABLE 3.

Compliance rate and summary of adverse events—Safety Population.

Compliance rate	Total (n = 381)	TEL/AML/CHTD, (n = 192)	TEL/AML, (n = 189)	p
Baseline – weeks 2	98.0 ± 5.8	97.9 ± 5.2	98.1 ± 6.3	NS
Week 2 – weeks 4	98.8 ± 4.7	98.8 ± 5.3	98.7 ± 4.0	NS
Week 4 – weeks 8	98.7 ± 4.7	98.7 ± 4.6	98.7 ± 4.7	NS
Total period	98.2 ± 4.2	98.0 ± 4.5	98.4 ± 3.8	NS

Adverse events	Total (n = 381)	TEL/AML/CHTD (n = 192)	TEL/AML (n = 189)	p
TEAE, n(%)	48(12.6)	30(15.6)	18(9.5)	.0728
Treatment related AEs, n(%)	30(7.9)	20(10.4)	10(5.3)	.0633
SAEs, n(%)	2(0.5)	1 (0.5)	1 (0.5)	1.000
Treatment‐related SAEs, n(%)	0(0)	0(0)	0(0)
Discontinued due to AE	0(0)	0(0)	0(0)

Abbreviations: AEs, TEAEs which have the relationship with IP such as ‘Certainly’, ‘Probably’, ‘Possibly’, ‘Unlikely’ or ‘Unassessable/Unclassifiable; TEAE, Treatment emergent adverse event; SAE, Serious adverse event Treatment‐Related; TEL/AML, telmisartan/amlodipine; TEL/AML/CHTD, telmisartan/amlodipine/chlorthalidone.